American ginseng (Panax Quinquefolius L.) extract alters mitogen-activated protein kinase cell signaling and inhibits proliferation of MCF-7-cells

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 2, 2007, Pages 147-155

  King, Mandy L ^a   Murphy, Laura L ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

American ginseng; Breast cancer; MAPK; MCF 7; Panax quinquefolius L.; Raf kinase inhibitory protein; RKIP

Indexed keywords

CELL PROTEIN; GINSENG EXTRACT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHOTRANSFERASE INHIBITOR; RAF PROTEIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GINSENG; HUMAN; HUMAN CELL; IC 50; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; PANAX; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHORYLATION; PLANT EXTRACTS; RNA, MESSENGER;

EID: 33947364766     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 27:1-19, 2004.
2. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58:1685-1693, 1999.
3. Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 9:259-274, 2004.
4. Lee YN, Lee HY, Chung HY, Kim SI, Lee SK, Park BC, Kim KW. In vitro induction of differentiation by ginsenosides in FO teratocarcinoma cells. Eur J Cancer 32A:1420-1428, 1996.
5. Lee JY, Shin JW, Chun KS, Park KK, Chung WY, Bang YJ, Sung JH, Surh YJ. Antitumor promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin. Carcinogenesis 26:359-67, 2005.
6. Kim YH, Park KH, Rho HM. Transcriptional activation of the Cu,Zn-superoxide dismutase gene through the AP2 site by ginsenoside Rb2 extracted from a medicinal plant, Panax ginseng. J Biol Chem 271:24539-24543, 1996.
7. Kitts DD, Wijewickreme AN, Hu C. Antioxidant properties of a North American ginseng extract. Mol Cell Biochem 203:1-10, 2000.
8. Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. Integr Cancer Ther 2:247-267, 2003.
9. Oh M, Choi YH, Choi S, Chung H, Kim K, Kim SI, Kim DK, Kim ND. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol 14:869-875, 1999.
10. Yim HW, Jong HS, Kim TY, Choi HH, Kim SG, Song SH, Kim J, Ko SG, Lee JW, Kim TY, Bang YJ. Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res 65:1952-1960, 2005.
11. Keum YS, Han SS, Chun KS, Park KK, Park JH, Lee SK, Surh YJ. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat Res 523:75-85, 2003.
12. Popovich DG, Kitts DD. Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch Biochem Biophys 406:1-8, 2002.
13. Fujimoto J, Sakaguchi H, Aoki I, Toyoki H, Khatun S, Tamaya T. Inhibitory effect of ginsenoside-Rb2 on invasiveness of uterine endometrial cancer cells to the basement membrane. Eur J Gynaecol Oncol 22:339-341, 2001.
14. Duda RB, Kang SS, Archer SY, Meng S, Hodin RA. American ginseng transcriptionally activates p21 mRNA in breast cancer cell lines. J Korean Med Sci 16 Suppl:S54-60, 2001.
15. Oh JI, Chun KH, Joo SH, OH YT, Lee SK. Caspase-3-dependent protein kinase C delta activity is required for the progression of ginsenoside-Rh2-induced apoptosis in SK-HEP-1 cells. Cancer Lett 230:228-238, 2005.
16. Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, Im DS. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 27:429-435, 2004.
17. Lee KD, Huemer RP. Antitumoral activity of Panax ginseng extracts. Jap J Pharmacol 21:299-302, 1971.
18. Duda RB, Taback B, Kessel B, Dooley DD, Yang H, Marchiori J, Slomovic BM, Alvarez JG. pS2 expression induced by American ginseng in MCF-7 breast cancer cells. Ann Surg Oncol 3:515-520, 1996.
19. Duda RB, Zhong Y, Navas V, Li MZC, Toy BR, Alavarez JG American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol 72:230-239, 1999.
20. King ML, Adler SR, Murphy LL. Extraction-dependent effects of American ginseng on human breast cancer cell proliferation and estrogen receptor activation. Integr Cancer Ther 5:236-243, 2006.
21. Lee Y, Jin Y, Lim W, Ji S, Choi S, Jang S, Lee S. A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. J Steroid Biochem Mol Biol 84:463-468, 2003.
22. Chan RY, Chen WF, Dong A, Guo D, Wong MS. Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab 87:3691-3695, 2002.
23. Lee YJ, Jin YR, Lim WC, Park WK, Cho JY, Jang S, Lee SK. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch Pharm Res 26:58-63, 2003.
24. Lim TS, Na K, Choi EM, Chung JY, Hwang JK. Immunomodulating activities of polysaccharides isolated from Panax ginseng. J Med Food 7:1-6, 2004.
25. Shin JY, Song JY, Yun YS, Yang HO, Rhee DK, Pyo S. Immunostimulating effects of acidic polysaccharides extract of Panax ginseng on macrophage function. Immunopharmacol Immunotoxicol 24:469-482, 2002.
26. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signaling by RKIP. Nature 401:173-177, 1999.
27. Parkin DM. International variation. Oncogene 23:6329-6340, 2004.
28. Lengacher CA, Bennet MP, Kip KE, Beraducci A, Cox CE. Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 29:1445-1452, 2002.
29. Rakovitch E, Pignol JP, Chartier C, Ezer M, Verma S, Dranitsaris G, Clemons M. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 90:139-148, 2005.
30. Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W. Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 163:645-653, 2006.
31. Corbit R, Ebbs S, King ML, Murphy LL. The influence of lead and arsenite on the inhibition of human breast cancer MCF-7 cell proliferation by American ginseng root (Panax quinquefolius L.). Life Sci 78:1336-1340, 2006.
32. Corbit RM, Ferreira JF, Ebbs SD, Murphy LL. Simplified extraction of ginsenosides from American ginseng (Panax quinquefolius L.) for high-performance liquid chromatography-ultraviolet analysis. J Agric Food Chem 53:9867-9873, 2005.
33. Qian T, Cai Z, Wong RNS, Mak NK, Jiang ZH. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatography 816:223-232, 2005.
34. Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol 50:1155-1160, 1998.
35. Bae EA, Han MJ, Kim EJ, Kim DH. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res 27:61-67, 2004.
36. Hasegawa H. Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 95:153-157, 2004.
37. Li L, Shen Y-X, Zhang J-L, Wang S-S, Guo D-A. High-performance liquid chromatographic assay for the active saponins from Panax notoginseng in rat tissues. Biomed Chromatography 20:327-335, 2006.
38. Park JA, Lee KY, Oh YJ, Kim KW, Lee SK. Activation of caspase-3 protease via a Bcl-2 insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett 121:73-81, 1997.
39. Tawab MA, Bahr T, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. J Pharmacol Exp Therap 31:1065-1071, 2003.
40. Dhillon AS, Kolch W. Untying the regulation of the Raf-1 kinase. Arch Biochem Biophys 404:3-9, 2002.
41. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263-1293, 2003.
42. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W. Mechanism of suppression of the Raf/MEK/Extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 20:3079-3085, 2000.
43. Trakul N, Menard RE, Schade GR, Qian Z, Rosner MR. Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation. J Biol Chem 280:24931-24940, 2005.
44. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xl downregulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res 64:7117-7126, 2004.
45. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24:2121-2143, 2005.
46. Zhang L, Fu Z, Binkley C, Giordano T, Burant CF, Logsdon CD, Simeone DM. Raf kinase inhibitory protein inhibits β-cell proliferation. Surgery 136:708-715, 2004.
47. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Zeller ET Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95:879-889, 2003.
48. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch W. Reduction of raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Cin Cancer Res 11:7392-7397, 2005.
49. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to durg-induced apoptosis. J Biol Chem 279:17515-17523, 2004.
50. Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches the raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574-579, 2003.
51. Corbit KC, Trakul N, Eves EM, Diaz B, Marshall M, Rosner MR. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem 278:13061-13068, 2003.
52. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-KB-inducing kinase and TAK1 and inhibits NF-κB activation. Mol Cell Biol 21:7207-7217, 2001.